Drug Trial Radar · NCT03252626
Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke
Last checked: Nov 19, 2026Latest source record: Apr 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
950
Planned (sponsor's estimate)
Start
Apr 18, 2024
Primary completion
Dec 31, 2024
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- The First Hospital of Jilin UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Ischemic stroke has a variety of treatments and currently drug therapy is one of the main treatments.A number of clinical studies have proved that alprostadil (PGE1) has pharmacological effects of significant dilation of blood vessels, inhibition of plate aggregation, anti-atherosclerosis and increased cerebral blood flow.Evaluate the 90-days efficacy by comparing two groups of patients'(one with alprostadil,another with placebo) mRS.
Conditions
- Stroke
Interventions
AlprostadilDrug
Alprostadil injection USP for intravascular infusion contains 500 micrograms Alprostadil, more commonly known as prostaglandin E1. Vasodilation, inhibition of platelet aggregation are among the most notable of these effects. 2ml Alprostadil injection added into 10ml 0.9% saline.
Normal salineDrug
2ml normal saline injection added into 10ml 0.9% saline.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Modified Rankin Scale at Day 90Time frame: day 90
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.